Genervon Biopharmaceuticals has continued to provide GM604 to Doctors of named ALS patients around the world since our December 10, 2015 Press Release...
GM604 to Be Granted "Orphan Drug" Status in Europe
Updated Summary on Genervon Science & GM604
Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease
FDA Grants "Orphan Drug" Designation for Genervon's Breakthrough Multi-Target ALS Bio-Drug GM604
FDA Granted Fast Track Designation for Genervon's Breakthrough Biotechnology Multi-Target ALS Drug GM604 Expediting Drug Approval Process
FDA Approves Broadly Inclusive Phase IIa ALS Clinical Trial with GM604, a Biotechnology Innovation
Multiple Target ALS Drug Ready for Genervon's Phase 2 Trial
Multiple targets, highly effective, breakthrough therapy for ALS sufferers may now be within reach. Winston Ko, the CEO of Genervon Biopharmaceuticals, will be presenting on Friday at the Neurotech Conference in San Francisco that its endogenous regulatory drug GM604 modulates over 80 ALS related gene targets interactively and dynamically through 12 pathways and up to 22 biological processes, including neurogenesis, neural development, signaling and transport...